5.21.20 | Policy
SWHR Testimony on HHS Appropriations for FY2021
This week, SWHR President and CEO Kathryn G. Schubert, MPP, provided outside witness testimony on behalf of the Society for […]
5.19.20 | Research and Clinical Trials
SWHR Comments on Cures 2.0 Legislation
SWHR provided Representative Diana DeGette (D-CO) and Representative Fred Upton (R-MI) with initial feedback today in response to their recent […]
4.21.20 | Alzheimer's Disease
SWHR Comments on AHRQ Draft Report on Dementia Caregiving
SWHR provided comments on the Care Interventions of People with Dementia and for their Caregivers draft report by the Agency […]
4.6.20 | Policy
FDA’s Quest to Address Disparities in Medical Devices for Women
Recognizing sex and gender disparities and the pressing issues they present for the health of women, the FDA recently launched the Health of Women Program to foster and advance device innovation for women.
3.18.20 | Coronavirus
SWHR Urges Inclusion of Pregnant and Lactating Women in COVID-19 Research
SWHR and other members of the Coalition to Advance Maternal Therapeutics (CAMT) urged the National Institutes of Health (NIH) and […]
3.13.20 | Alzheimer's Disease
SWHR Feedback to Senate Finance Health Subcommittee on Alzheimer’s Research Priorities
SWHR sent comments to the Senate Finance Subcommittee on Health Care in response to its call for feedback related to […]
3.9.20 | Policy
How Options for Disease Screening and Diagnosis Can Affect Women’s Health
Understanding the complicated world of screening and diagnostic testing can help patients better grasp the possibilities for their care.
2.27.20 | Policy
Ovarian Cancer: Challenges in Diagnostic Innovation
Most women will never be screened for ovarian cancer. Unlike with breast and cervical cancers, ovarian cancer research has struggled to produce reliable methods of screening.
2.4.20 | Policy
Ovarian Cancer: Outdated Diagnostics for a Deadly Disease
Over 20,000 women will be diagnosed with ovarian cancer this year in the United States, and less than half of them will still be alive in five years.
1.8.20 | Policy
No ‘Best’ Framework for Assessing Value of Health Care Innovations, NPC Report Says
A report from the National Pharmaceutical Council (NPC) concludes that there is no “best” framework for determining the value of a health care product.
